Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet: A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS

Douglas T. Dieterich, Michael A. Poles, Edward A. Lew, Sarah Martin-Munley, Jeanne Johnson, David Nix, Michael J. Faust

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Ten patients with AIDS and cytomegalovirus (CMV) gastrointestinal infection were included in an open-label study to evaluate the safety, efficacy, and pharmacokinetics of 90 mg of intravenous foscarnet/kg of body weight twice daily accompanied by (pre)hydration of 500 to 750 ml. Efficacy was documented endoscopically, while safety was evaluated clinically by patient reports and physical and laboratory observation. The pharmacokinetics of foscarnet was evaluated after the first dose and following approximately 20 days of therapy. Nine patients (90%) responded histopathologically, nine (90%) responded endoscopically, and nine (90%) responded symptomatically to foscarnet therapy. Adverse events resulted in discontinuance of medication in the case of one patient. The mean maximal concentration was 621 μM following the first dose and 687 μM at steady state (P = 0.11). The apparent elimination rate constant and elimination half-life were not different between dose I and steady state. There were no significant changes in foscarnet excretion or renal clearance between dose I and steady state. The steady-state volume of distribution was 23.4 liters following the first dose and 19.0 liters at steady state (P < 0.002). Twice-daily foscarnet appeared to be safe and efficacious in the treatment of CMV gastrointestinal disease in this study, resulting in endoscopic or histologic improvement in 9 of the 10 (90%) patients. Minor changes in clearance and volume of distribution noted at steady state compared to single-dose administration are readily explained by study design, known information about foscarnet pharmacokinetics, and changes in body weight and creatinine clearance in the patients.

Original languageEnglish (US)
Pages (from-to)1226-1230
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number6
StatePublished - Jun 1 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Treatment of gastrointestinal cytomegalovirus infection with twice- daily foscarnet: A pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS'. Together they form a unique fingerprint.

  • Cite this